Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 19, 2009

WaferGen Launches Gene-Expression Profiling Service

  • WaferGen Biosystems introduced a new service for gene-expression profiling of thousands of genes using its SmartChip™ real-time PCR system. WaferGen will offer its pathway-specific gene panels to universities and pharmaceutical and diagnostic companies that are looking to discover and validate new biomarkers.

    WaferGen also reported that it is moving to a new facility to support the SmartChip services and the expansion of manufacturing and R&D functions.

    The new WaferGen SmartChip service will be made available to a few select customers in December and made more broadly available in the first quarter of 2010. The SmartChip service offerings will be expanded early next year to include a miRNA expression panel. Researchers will get early access to the technology and the benefit of new and upcoming gene panels.

    The initial product to be run on the SmartChip platform is the SmartChip Human Oncology Gene Panel that provides pathway based gene-expression profiling for oncology. It may also be used for immunology, metabolic, and stem cell research.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »